Pancreatic Cancer Research

ResearcherTongji UniversityActive in the last 2 years

Jiujie Cui

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-0853-7569; OpenAlex author ID A5047704890. Sources: OpenAlex.

Their work

Papers
54 (first author 6, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
118
Papers, trials and grants by year

2012: 2 papers · 2013: 3 papers · 2014: 4 papers · 2015: 3 papers · 2016: 2 papers · 2017: 4 papers · 2018: 2 papers · 2019: 3 papers · 2020: 5 papers · 2021: 5 papers · 2022: 9 papers · 2023: 3 papers · 2024: 4 papers · 2025: 1 paper · 2026: 4 papers

Papers 50 of 54

  1. The bile acid TUDCA promotes chemoresistance and predicts survival through MAPK signaling in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00018-026-06210-4↗
  2. Reversal of KRAS G12D inhibitor resistance by nimotuzumab via MEK/ERK-mediated unfolded protein response in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2026.218684↗
  3. Chinese expert consensus on precision testing and molecular diagnosis of pancreatic cancer (2025). Co-author DOI 10.1038/s41416-026-03522-x↗
  4. KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRAS G12D-mutant pancreatic cancer: a phase 1b/2 trial. Co-author DOI 10.1038/s41591-026-04538-9↗
  5. Upregulation of Lactobacillus spp. in gut microbiota as a novel mechanism for environmental eustress-induced anti-pancreatic cancer effects. Co-author DOI 10.1080/19490976.2025.2470372↗
  6. Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma… Co-author DOI 10.1038/s41392-024-01948-4↗
  7. Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s44321-024-00060-y↗
  8. Activation of the PI3K/AKT signaling pathway by ARNTL2 enhances cellular glycolysis and sensitizes pancreatic adenocarcinoma to erlotinib. Last author DOI 10.1186/s12943-024-01965-5↗
  9. The Role of Bile Acids in Pancreatic Cancer. Co-author DOI 10.2174/0115680096281168231215060301↗
  10. PLA2G2A+ cancer-associated fibroblasts mediate pancreatic cancer immune escape via impeding antitumor immune response of CD8+ cytotoxic T cells. Co-author DOI 10.1016/j.canlet.2023.216095↗
  11. Chemotherapeutic drugs-induced pyroptosis mediated by gasdermin E promotes the progression and chemoresistance of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2023.216206↗
  12. Cuproptosis-related lncRNAs are correlated with tumour metabolism and immune microenvironment and predict prognosis in pancreatic cancer patients. Co-author DOI 10.1049/syb2.12068↗
  13. Characterization of DNA damage response deficiency in pancreatic cancer patients from China. Co-author DOI 10.1002/cac2.12238↗
  14. Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2022.103897↗
  15. Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer. Co-author DOI 10.1016/j.jncc.2022.08.006↗
  16. Prediction of Survival and Tumor Microenvironment Infiltration Based on Pyroptosis-Related lncRNAs in Pancreatic Cancer. Co-author DOI 10.1155/2022/5634887↗
  17. HDACs/mTOR inhibitor synergizes with pyrotinib in HER2-positive pancreatic cancer through degradation of mutant P53. Co-author DOI 10.1186/s12935-022-02807-4↗
  18. Cuproptosis-related lncRNAs are correlated with metabolism and immune microenvironment and predict prognosis in pancreatic cancer patients Co-author DOI 10.21203/rs.3.rs-1645540/v1↗
  19. A novel angiogenesis-based molecular signature related to prognosis and tumor immune interactions of pancreatic cancer. Co-author DOI 10.3389/fcell.2022.1001606↗
  20. Association of aging-related genes with prognosis and immune infiltration in pancreatic adenocarcinoma. Co-author DOI 10.3389/fcell.2022.942225↗
  21. A Novel Molecular Signature of Cancer-Associated Fibroblasts Predicts Prognosis and Immunotherapy Response in Pancreatic Cancer. Last author DOI 10.3390/ijms24010156↗
  22. Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response. Co-author DOI 10.1038/s41421-021-00271-4↗
  23. Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china. Co-author DOI 10.1080/14737167.2020.1812386↗
  24. A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-021-08375-6↗
  25. A narrative review of Safety management of 1 L platinum-based chemotherapy and maintenance olaparib in BRCA mutated advanced pancreatic cancer. Co-author DOI 10.21037/tcr-20-3478↗
  26. CSE1L, as a novel prognostic marker, promotes pancreatic cancer proliferation by regulating the AKT/mTOR signaling pathway. Co-author DOI 10.7150/jca.54482↗
  27. RNA-binding protein Musashi2 regulates Hippo signaling via SAV1 and MOB1 in pancreatic cancer. Co-author DOI 10.1007/s12032-020-01384-8↗
  28. A novel KDM5A/MPC-1 signaling pathway promotes pancreatic cancer progression via redirecting mitochondrial pyruvate metabolism. Co-author DOI 10.1038/s41388-019-1051-8↗
  29. Caveolin-2 is regulated by BRD4 and contributes to cell growth in pancreatic cancer. Co-author DOI 10.1186/s12935-020-1135-0↗
  30. Lysine demethylase 2 (KDM2B) regulates hippo pathway via MOB1 to promote pancreatic ductal adenocarcinoma (PDAC) progression. Last author DOI 10.1186/s13046-019-1489-0↗
  31. Coordinated silencing of the Sp1-mediated long noncoding RNA MEG3 by EZH2 and HDAC3 as a prognostic factor in pancreatic ductal adenocarcinoma. Co-author DOI 10.20892/j.issn.2095-3941.2019.0427↗
  32. MST1 Suppresses Pancreatic Cancer Progression via ROS-Induced Pyroptosis. Co-author DOI 10.1158/1541-7786.mcr-18-0910↗
  33. Patient-derived xenografts: a valuable platform for clinical and preclinical research in pancreatic cancer. First author DOI 10.21037/cco.2019.02.04↗
  34. JQ1 effectively inhibits vasculogenic mimicry of pancreatic ductal adenocarcinoma cells via the ERK1/2-MMP-2/9 signaling pathway both in vitro and in vivo. Co-author PMID 30899402↗
  35. A novel feedback loop between high MALAT-1 and low miR-200c-3p promotes cell migration and invasion in pancreatic ductal adenocarcinoma and is predictive of po… Co-author DOI 10.1186/s12885-018-4954-9↗
  36. A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.23984↗
  37. The Novel KLF4/MSI2 Signaling Pathway Regulates Growth and Metastasis of Pancreatic Cancer. First author DOI 10.1158/1078-0432.ccr-16-1064↗
  38. The critical role and potential target of the autotaxin/lysophosphatidate axis in pancreatic cancer. First author DOI 10.1177/1010428317694544↗
  39. Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancrea… Co-author DOI 10.18632/oncotarget.14069↗
  40. Correlated high expression of FXR and Sp1 in cancer cells confers a poor prognosis for pancreatic cancer: A study based on TCGA and tissue microarray. Co-author DOI 10.18632/oncotarget.16633↗
  41. Expression profile and prognostic value of SAV1 in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s13277-016-5457-4↗
  42. HGF/Met and FOXM1 form a positive feedback loop and render pancreatic cancer cells resistance to Met inhibition and aggressive phenotypes. Co-author DOI 10.1038/onc.2016.14↗
  43. Suppressed expression of LDHB promotes pancreatic cancer progression via inducing glycolytic phenotype. Co-author DOI 10.1007/s12032-015-0589-8↗
  44. Activation of vitamin D receptor signaling downregulates the expression of nuclear FOXM1 protein and suppresses pancreatic cancer cell stemness. Co-author DOI 10.1158/1078-0432.ccr-14-2437↗
  45. Hippo transducer TAZ promotes epithelial mesenchymal transition and supports pancreatic cancer progression. First author DOI 10.18632/oncotarget.5772↗
  46. Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1053/j.gastro.2014.04.048↗
  47. FOXM1c promotes pancreatic cancer epithelial-to-mesenchymal transition and metastasis via upregulation of expression of the urokinase plasminogen activator sys… Co-author DOI 10.1158/1078-0432.ccr-13-2311↗
  48. FOXM1 promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression. Co-author DOI 10.1158/1078-0432.ccr-13-2407↗
  49. A novel KLF4/LDHA signaling pathway regulates aerobic glycolysis in and progression of pancreatic cancer. First author DOI 10.1158/1078-0432.ccr-14-0186↗
  50. Dysregulated expression of FOXM1 isoforms drives progression of pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-12-3859↗

Closest collaborators

The 25 strongest of 118 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Liwei Wang · 18 shared papers, 2019–2026 · strength 2.76
  2. Tiebo Mao · 16 shared papers, 2021–2024 · strength 2.23
  3. Xiaofei Zhang · 15 shared papers, 2021–2024 · strength 2.17
  4. Shengbai Xue · 12 shared papers, 2022–2026 · strength 2.15
  5. Feng Jiao · 17 shared papers, 2015–2022 · strength 1.69
  6. Weiyu Ge · 11 shared papers, 2022–2024 · strength 1.61
  7. Ming Quan · 11 shared papers, 2015–2024 · strength 1.09
  8. Liwei Wang · 7 shared papers, 2018–2025 · strength 0.92
  9. Liwei Wang · 11 shared papers, 2012–2022 · strength 0.86
  10. Jiayu Yao · 7 shared papers, 2021–2022 · strength 0.84
  11. Yanling Wang · 4 shared papers, 2022–2026 · strength 0.83
  12. Haiyan Yang · 6 shared papers, 2019–2024 · strength 0.74
  13. Ting Han · 7 shared papers, 2017–2021 · strength 0.71
  14. Meng Zhuo · 6 shared papers, 2017–2020 · strength 0.60
  15. Keping Xie · 11 shared papers, 2012–2020 · strength 0.57
  16. Yiyi Liang · 4 shared papers, 2020–2025 · strength 0.57
  17. Jiong Hu · 5 shared papers, 2020–2022 · strength 0.55
  18. Yong Gao · 8 shared papers, 2014–2020 · strength 0.52
  19. Liwei Wang · 3 shared papers, 2022–2024 · strength 0.50
  20. Yu Wang · 4 shared papers, 2019–2022 · strength 0.48
  21. Dacheng Xie · 8 shared papers, 2012–2020 · strength 0.46
  22. Shumin Li · 3 shared papers, 2022–2023 · strength 0.41
  23. Yanling Wang · 3 shared papers, 2022–2023 · strength 0.41
  24. Yongwei Sun · 4 shared papers, 2021–2022 · strength 0.41
  25. Deliang Fu · 4 shared papers, 2021–2022 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.